Clinical Trial Update: Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial update evaluating tislelizumab as consolidation therapy after liver-directed treatment for hepatocellular carcinoma, with recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Tislelizumab (tislelizumab)

Snippet

Sponsor: Rutgers, The State University of New Jersey | Conditions: Carcinoma, Hepatocellular, Liver Cell Carcinoma | Phase 2 | Status: RECRUITING